Abstract
Purpose
To identify the predictive role of sarcopenia in long-term survival among rectal cancer patients who underwent surgery based on available evidence.
Methods
The Medline, EMBASE and Web of Science databases were searched up to October 20, 2023, for relevant studies. Overall survival (OS), disease-free survival (DFS) and cancer-specific survival (CSS) were the endpoints. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined to evaluate the association between sarcopenia and survival.
Results
Fifteen studies with 4283 patients were included. The pooled results demonstrated that preoperative sarcopenia significantly predicted poorer OS (HR = 2.07, 95% CI = 1.67–2.57, P<0.001), DFS (HR = 1.85, 95% CI = 1.39–2.48, P<0.001) and CSS (HR = 1.83, 95% CI = 1.31–2.56, P<0.001). Furthermore, subgroup analysis based on neoadjuvant therapy indicated that sarcopenia was a risk factor for worse OS and DFS in patients who received (OS: HR = 2.44, P<0.001; DFS: HR = 2.16, P<0.001) but not in those who did not receive (OS: HR = 2.44, P<0.001; DDFS: HR = 1.86, P = 0.002) neoadjuvant chemoradiotherapy. In addition, subgroup analysis based on sample size and ethnicity showed similar results.
Conclusion
Preoperative sarcopenia is significantly related to poor survival in surgical rectal cancer patients and could serve as a novel and valuable predictor of long-term prognosis in these patients.
Publisher
Public Library of Science (PLoS)
Reference45 articles.
1. Colorectal cancer statistics, 2023;RL Siegel;CA Cancer J Clin
2. Cancer statistics in China, 2016;RS Zheng;Zhonghua Zhong Liu Za Zhi
3. Prevalence and trend of gastrointestinal malignant tumors in the elderly over 75 years old in China;Y Zheng;Zhonghua Wei Chang Wai Ke Za Zhi,2016
4. Cancer statistics in China and United States, 2022: profiles, trends, and determinants;C Xia;Chin Med J (Engl),2022
5. An investigation of the clinical nutritional practices of oncologists and the management of cancer-related malnutrition in inpatient care;AS Almasaudi;Eur Rev Med Pharmacol Sci,2023